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Introduction {#sec1}
============

Ubiquitin (Ub) chains linked via the N-terminal methionine (Met1) of Ub (Met1-Ub, also termed linear Ub) and lysine 63 (Lys63-Ub) facilitate innate immune signaling initiated by pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) and nucleotide-oligomerization domain (NOD)-like receptors and cytokine receptors such as tumor necrosis factor (TNF) receptor 1 (TNFR1) ([@bib14], [@bib22]). The linear Ub chain assembly complex (LUBAC), composed of HOIL-1, HOIP, and SHARPIN, is the only known Ub ligase to generate Met1-Ub ([@bib16], [@bib21], [@bib26], [@bib44]). LUBAC activity is counterbalanced by the Met1-specific deubiquitinase (DUB) OTULIN ([@bib15], [@bib24], [@bib36]), which binds to the catalytic subunit HOIP via interactions between the HOIP peptide:N-glycanase/UBA- or UBX-containing proteins (PUB) domain and a PUB-interacting motif (PIM) in OTULIN ([@bib12], [@bib38]). The importance of Met1-Ub in immune signaling is underscored by identification of mutations within the LUBAC-encoding genes in human patients with immunological disease ([@bib5], [@bib6]). Lys63-Ub can be generated by Ub ligases that interact with the dimeric E2 complex Ubc13/Uev1a, which exclusively conjugates this linkage ([@bib10]). Lys63-Ub is particularly important in MyD88-dependent immune-signaling pathways activated by TLRs and interleukin-1 receptors (IL-1R) whereas the role of Lys63-Ub in the NOD-containing protein 2 (NOD2) and TNFR1 pathways is not fully understood ([@bib14], [@bib50]).

NOD2 is an intracellular bacteria-sensing PRR that recognizes MDP (muramyl dipeptide) constituents of bacterial peptidoglycan and plays a critical role in gastro-intestinal immunity ([@bib33]). Upon stimulation, NOD2 binds receptor-interacting protein kinase 2 (RIPK2, also known as RIP2 or RICK), leading to recruitment of several Ub ligases including the inhibitor of apoptosis (IAP) proteins, cIAP1, cIAP2, and XIAP ([@bib3], [@bib8]). XIAP is indispensable for NOD2 pathway functionality, where it ubiquitinates RIPK2 to facilitate recruitment of LUBAC ([@bib2], [@bib8]). In turn, LUBAC assembles Met1-Ub on RIPK2 to enable downstream signal transduction ([@bib15]). Additionally, TRAF2, ITCH, cIAP1/2, TRAF6, and PELI3 are reported to contribute to the assembly of Lys63-Ub on RIPK2, but their individual contribution to this process and to NOD2 signaling is not fully resolved ([@bib3], [@bib19], [@bib42], [@bib48], [@bib51]). A central regulatory point for productive innate immune signaling and transcription of nuclear factor-κB (NF-κB) target genes is the activation of the IKK (IκB kinase) complex. IKK activation is dependent on phosphorylation by the TAB/TAK1 complex that interacts with Lys63-Ub and on the conjugation of Met1-Ub by LUBAC, which is bound by the IKK subunit NEMO (also known as IKKγ; [@bib14], [@bib22]).

For appropriate and beneficial innate immune signaling, the assembly of Ub chains at receptor complexes must be carefully counterbalanced by DUBs. The linkage-selective DUBs OTULIN, CYLD, and A20 regulate various aspects of pro-inflammatory signaling ([@bib14], [@bib18]). The A20 gene (*TNFAIP3*) is a transcriptional target of NF-κB and A20 functions as a part of the negative feedback mechanism to terminate signaling ([@bib18], [@bib29]). Contrary to this, OTULIN functions to restrict the accumulation of Met1-Ub at basal conditions and early during signaling, and *OTULIN* expression is not induced by stimulation of NF-κB activity ([@bib15], [@bib24], [@bib36]).

CYLD is a bona fide tumor suppressor and negatively regulates pro-inflammatory signaling ([@bib4], [@bib18]). CYLD belongs to the USP (Ub-specific protease) family of DUBs ([@bib7], [@bib28], [@bib45]) and in vitro cleaves Lys63-Ub and Met1-Ub with similar efficiency while displaying less activity toward Lys11-Ub and Lys48-Ub ([@bib27], [@bib35], [@bib37]). Unexpectedly, CYLD was recently reported to interact with HOIP, the catalytic subunit of LUBAC, and to inhibit LUBAC-dependent activation of NF-κB ([@bib40]).

Here, we show that, although CYLD is associated with LUBAC through HOIP binding, CYLD does not regulate ubiquitination of LUBAC components. Instead, CYLD counteracts Lys63-Ub and Met1-Ub conjugated to the LUBAC substrate RIPK2 to restrict signaling and cytokine production. Our results suggest that LUBAC not only is a Met1-specific E3 but also, through its associated DUBs, coordinates Met1- and Lys63-linked Ub chain assembly at signaling complexes.

Results {#sec2}
=======

CYLD Antagonizes LUBAC Function but Does Not Affect HOIP Ubiquitination {#sec2.1}
-----------------------------------------------------------------------

LUBAC function is restricted by OTULIN through its docking to the PUB domain of HOIP ([@bib12], [@bib38]). Unexpectedly, CYLD also interacts with LUBAC via the HOIP PUB domain and mutations, such as N102D, that interfere with OTULIN binding also interfere with CYLD binding ([@bib40]; [Figures 1](#fig1){ref-type="fig"}A--1C). Moreover, CYLD can, akin to OTULIN, suppress LUBAC-induced NF-κB activation through its DUB activity ([@bib40]; [Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}A). This together with the fact that CYLD cleaves Lys63-Ub and Met1-Ub in vitro ([@bib27], [@bib37]; [Figure S1](#mmc1){ref-type="supplementary-material"}B) implies that CYLD and OTULIN might function in a similar manner to control Met1-Ub conjugation by LUBAC.

To investigate this, we initially tested whether CYLD, like OTULIN, regulates HOIP ubiquitination. Surprisingly, depletion of CYLD in U2OS/NOD2 cells (a cell line expressing doxycycline \[DOX\]-inducible HA-NOD2 that responds to the NOD2 ligand L18-MDP without addition of DOX due to slight leakiness of the promoter; [@bib15]) had no effect on HOIP ubiquitination under basal conditions or after receptor stimulation ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}C). In contrast, OTULIN depletion led to extensive accumulation of Met1-Ub on HOIP ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}C). Affinity purification of Ub conjugates via linkage-specific Ub binders (SUBs) selective for Met1-Ub (M1-SUB; [@bib15]) or Lys63-Ub (K63-SUB; [@bib39], [@bib43]) showed that Met1-Ub, but not Lys63-Ub, accumulated on LUBAC ([Figure 1](#fig1){ref-type="fig"}E). Analysis of THP1 human monocytic cells or HCT-116 human colon carcinoma cells, which both express NOD2 endogenously, confirmed that CYLD was not involved in controlling Met1-Ub accumulation on HOIP whereas OTULIN was indispensable ([Figures 1](#fig1){ref-type="fig"}F, 1G, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E). Accordingly, ectopic expression of inactive OTULIN (C129A), but not inactive CYLD (C601A), caused extensive accumulation of Met1-Ub on HOIP ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}F). This prompted us to explore the role of CYLD in regulating the NOD2 pathway, which relies on LUBAC.

CYLD Activity Controls NOD2 Signaling {#sec2.2}
-------------------------------------

CYLD has been reported to inhibit RIPK2-induced signaling when overexpressed ([@bib1]), but the function of endogenous CYLD in NOD2 signaling remains unexplored and its role as a DUB is unknown. Depletion of CYLD showed that CYLD limits productive signaling after NOD2 stimulation as determined by accumulation of transcripts from the NF-κB-responsive genes *TNF* and *CXCL8* and production of IL-8 (encoded by *CXCL8*; [Figures 2](#fig2){ref-type="fig"}A and 2B). The requirement for CYLD in restricting NOD2 responses was further validated in CYLD-deficient bone-marrow-derived dendritic cells (BMDCs), which produced markedly higher levels of pro-inflammatory cytokines than their wild-type counterparts upon NOD2 activation ([Figure 2](#fig2){ref-type="fig"}C).

OTULIN depletion also led to increased IL-8 production, but the effect was less pronounced as compared to CYLD depletion ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}A). Because both DUBs cleave Met1-Ub, we tested whether depletion of both DUBs would further deregulate NOD2 signaling. However, we found no additive or synergistic effect on IL-8 production or on MAP kinase and IKK signaling when both enzymes were depleted as compared to their individual depletion ([Figures 2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Interestingly, the depletion of CYLD did not affect IL-8 production after stimulation with TNF ([Figure 2](#fig2){ref-type="fig"}B), which might reflect a differential dependency of NOD2- and TNFR1-signaling pathways on LUBAC function ([@bib8], [@bib16]). To test this, the transcriptional response to NOD2 and TNFR1 stimulation was tested in HOIP-deficient HCT-116 (HOIP-KO) cells ([Figure 2](#fig2){ref-type="fig"}E). Transcriptional activation of *CXCL8* was ablated in HOIP-KO cells after NOD2 stimulation but was only reduced after TNF stimulation ([Figure 2](#fig2){ref-type="fig"}F). In fact, *CXCL8* was induced more than 25-fold in HOIP-KO cells in response to TNF. Also, measurement of NF-κB activity by a luciferase-based reporter showed that HOIP is required for NOD2-dependent NF-κB activation whereas TNF-induced NF-κB activation in HOIP KO cells is only partially decreased ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Reconstitution of the HOIP-KO cells with ectopic HOIP restored NF-κB activation in response to L18-MDP and TNF, showing that the signaling defect of the HOIP-KO cells was caused by the absence of HOIP ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

Next, we investigated the role of the DUB activity of CYLD in regulating NOD2 signaling. For this, the effect of wild-type CYLD (CYLD^WT^) and catalytic inactive CYLD (CYLD^C601A^) on nuclear translocation of the NF-κB subunit RelA and the production of IL-8 was determined. This showed that the ability of CYLD to antagonize productive NOD2 signaling relied on its catalytic activity ([Figures 3](#fig3){ref-type="fig"}A--3C, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Also, activation of NF-κB by ectopic XIAP, an essential Ub ligase for NOD2 signaling, was blocked by overexpression of CYLD^WT^, but not CYLD^C601A^, which increased NF-κB activity ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C). XIAP-induced NF-κB activity relies not exclusively on Met1-Ub ([@bib8]) but was also dependent on Ubc13-mediated formation of Lys63-Ub ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D), which might explain why OTULIN only partially inhibited XIAP-induced NF-κB activity ([Figure 3](#fig3){ref-type="fig"}D). CYLD and OTULIN were not inhibiting NF-κB activity per se because the DUBs did not appreciably inhibit NF-κB activity induced by an engineered non-cleavable Met1-Ub4 protein targeted to inactive XIAP ([@bib15]; [Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F).

CYLD Limits Extension of Ub Chains on RIPK Proteins {#sec2.3}
---------------------------------------------------

Because CYLD functioned as a DUB to limit NOD2-dependent signaling but did not regulate LUBAC ubiquitination, we asked whether depletion of CYLD would affect LUBAC substrate ubiquitination in response to receptor stimulation. Indeed, purification of Ub conjugates from control and CYLD-depleted cells stimulated with L18-MDP revealed that CYLD-depleted cells accumulated Ub-RIPK2 species containing Lys63 and Met1 linkages with a higher apparent molecular weight (MW) than observed in control cells, particularly at early time points ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). The effect of CYLD depletion on Ub-RIPK2 was strikingly different from the effect of OTULIN depletion, which promoted the accumulation of Ub-RIPK2 species but did not affect the MW of Ub-RIPK2 as compared with control cells ([@bib15]; [Figure 4](#fig4){ref-type="fig"}B).

*CYLD* is reported to be a transcriptional target of NF-κB in response to TNF and IL-1β treatment and to contribute to termination of signaling ([@bib23]). However, depletion of CYLD did not stabilize RIPK2 ubiquitination at late time points after NOD2 stimulation ([Figure 4](#fig4){ref-type="fig"}A). Also, NOD2 stimulation did not increase *CYLD* (or *OTULIN*) mRNA or protein levels whereas *TNFAIP3* (A20) mRNA and protein levels rapidly increased by the treatment ([Figures 4](#fig4){ref-type="fig"}C and 4D). This suggested that CYLD regulates ubiquitination at the initiation of signaling. In line with this, TNF treatment of CYLD-depleted cells led to accumulation of Ub-RIPK1 species with a higher apparent MW than observed in non-depleted cells within 10 min ([Figure 4](#fig4){ref-type="fig"}E), which coincided with the recruitment of CYLD to the TNFR-SC ([Figure 4](#fig4){ref-type="fig"}F). CYLD also co-purified with HA-NOD2 induced by DOX in U2OS/NOD2 cells, and under these conditions, CYLD levels were unaffected by the treatment ([Figure 4](#fig4){ref-type="fig"}G).

The ubiquitination of RIPK2 and RIPK1 after NOD2 and TNFR1 stimulation, respectively, is facilitated by several E3 Ub ligases, including XIAP and cIAPs. The continuous assembly of Ub chains within receptor-signaling complexes might therefore mask the regulation of ubiquitination by DUBs. To better assess the regulation of Ub chains by CYLD, we therefore treated cells with a Smac-mimetic compound (compound A \[CpA\]) to inhibit IAP function prior to receptor stimulation. When used at high concentrations (1 μM), CpA blocks RIPK2 ubiquitination in response to L18-MDP ([Figures 5](#fig5){ref-type="fig"}A, lanes 1--4, and [S5](#mmc1){ref-type="supplementary-material"}A) because the compound antagonizes the interaction of XIAP with RIPK2 in addition to inducing degradation of cIAPs ([@bib9]). Remarkably, depletion of CYLD under these conditions restored RIPK2 ubiquitination to comparable levels as in NOD2-stimulated cells not treated with CpA ([Figure 5](#fig5){ref-type="fig"}A, compare lane 8 with lanes 3 and 7). Depletion of OTULIN also led to accumulation of Ub-RIPK2 albeit to a lesser extent than when CYLD was depleted ([Figure 5](#fig5){ref-type="fig"}A, compare lane 12 with lanes 3 and 11). CpA also impaired the ubiquitination of RIPK1 in response to TNF, and depletion of CYLD partially restored RIPK1 ubiquitination ([Figures 5](#fig5){ref-type="fig"}B, compare lanes 4 and 8, and [S5](#mmc1){ref-type="supplementary-material"}B). This suggests that CYLD and OTULIN, especially at the NOD2 receptor complex, are highly active in regulating Ub chain stability.

CpA prevented the degradation of IκBα by L18-MDP in non-depleted cells but in CYLD-depleted cells IκBα levels were reduced after stimulation, suggesting that CYLD depletion restored productive signaling ([Figure 5](#fig5){ref-type="fig"}A, compare lanes 4 and 8). However, CpA inhibited IL-8 production in CYLD-depleted cells to a similar extent as in in control or OTULIN-depleted cells ([Figure 5](#fig5){ref-type="fig"}C). In contrast, CpA had no effect on IL-8 induced by phorbol myristate acetate (PMA) and ionomycin, indicating that the compound was not interfering with IL-8 production non-specifically ([Figure 5](#fig5){ref-type="fig"}D).

CYLD Trims Lys63- and Met1-Ub on RIPK2 {#sec2.4}
--------------------------------------

To address which Ub-linkage(s) CYLD regulates in the context of NOD2 pathway activation, we subjected Ub conjugates isolated with glutathione S-transferase (GST)-M1-SUB ([Figure 6](#fig6){ref-type="fig"}A) or GST-UBA^Ubq^ ([Figure 6](#fig6){ref-type="fig"}B) to Ub chains restriction (UbiCRest) analysis ([@bib20]). Incubation with OTULIN^WT^, but not inactive OTULIN^C129A^, resulted in a gel shift of Ub-RIPK2, but the digested Ub-RIPK2 from CYLD-depleted cells still migrated significantly slower than Ub-RIPK2 from control cells ([Figures 6](#fig6){ref-type="fig"}A, compare lanes 1 and 3 with lanes 7 and 9, and [6](#fig6){ref-type="fig"}B, compare lanes 2 and 5 with lanes 9 and 12). Additional Met1 linkages could thus not alone account for the slower migrating Ub-RIPK2 species in CYLD-depleted cells. Incubation with the Lys63-selective DUBs OTUD1 or AMSH^∗^ ([@bib30]) also resulted in a similar gel shift of Ub-RIPK2 isolated from control and CYLD-depleted cells ([Figure 6](#fig6){ref-type="fig"}B, compare lanes 2, 3, and 6 with lanes 9, 10, and 13). However, incubation with OTULIN plus OTUD1 or OTULIN plus AMSH^∗^ resulted in similar migration patterns of Ub-RIPK2 isolated from control and CYLD-depleted cells, indicating that CYLD restricts the deposition of both Lys63 and Met1 linkages on RIPK2 ([Figure 6](#fig6){ref-type="fig"}B, compare lanes 4 and 7 with lanes 11 and 14). The extent of Ub chain digestion and linkage specificity in the DUB reactions was determined by linkage-specific antibodies and by spiking into the reaction recombinant Met1-linked Ub4 with an N-terminal GST moiety. This indicated that OTUD1 and OTULIN cleaved the intended linkage largely to completion without detectable cross-reactivity with Met1- or Lys63-Ub, respectively ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Curiously, a substantial fraction of the high-MW signal detected by the Met1-Ub antibody disappeared in the OTUD1-treated samples even though OTUD1 did not digest GST-Met1-Ub4. This could reflect that Met1 linkages in general are conjugated to existing Lys63-Ub although the remaining signal in the OTULIN-treated samples suggests that the Met1-Ub antibody also can react with Ub chains other than Met1-Ub ([Figure S6](#mmc1){ref-type="supplementary-material"}A).

Notably, incubation of the purified Ub conjugates with AMSH^∗^ or OTUD1, but not with OTULIN, generated significant amounts of monoUb-RIPK2 and oligoUb-RIPK2, suggesting that Lys63 linkages are generated proximal to RIPK2 whereas Met1 linkages are only conjugated to polyubiquitinated RIPK2 ([Figures 6](#fig6){ref-type="fig"}B, 6C, and [S6](#mmc1){ref-type="supplementary-material"}A--S6C). The viral DUB vOTU disassembles all Ub linkages except Met1 ([@bib20]) and served as a positive control along with USP21 in the UbiCREST analysis, where they removed virtually all Ub moieties from RIPK2 ([Figures 6](#fig6){ref-type="fig"}A and 6C).

Lys63-Ub and Met1-Ub Are Individually Indispensable for NOD2 Signaling {#sec2.5}
----------------------------------------------------------------------

Lys63-Ub had been suggested to contribute to NOD2 signaling, and our investigation of CYLD's function supported this notion. However, the direct evidence for the requirement of the Lys63 linkage was still lacking. To address this, we expressed GFP-coupled variants of the K63-SUB and M1-SUB ([Figure 7](#fig7){ref-type="fig"}A) in order to interfere with the function of Lys63-Ub and Met1-Ub, respectively, as was previously reported ([@bib15], [@bib39]). Indeed, expression of GFP-K63-SUB inhibited the nuclear localization of RelA and production of IL-8 after NOD2 stimulation to a similar extent as GFP-M1-SUB despite being expressed at lower levels ([Figures 7](#fig7){ref-type="fig"}B--7D, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B). Gating of cells based on GFP expression revealed that low levels of GFP-K63-SUB were sufficient to block IL-8 production whereas GFP-M1-SUB inhibited IL-8 production only when highly expressed ([Figure 7](#fig7){ref-type="fig"}E). As expected, GFP-negative cells (not successfully transfected) responded similarly to NOD2 stimulation in all conditions ([Figures 7](#fig7){ref-type="fig"}C and 7E).

A substantial fraction of GFP-K63-SUB appeared to localize to the nucleus whereas GFP-M1-SUB was more evenly distributed between cytoplasm and nucleus ([Figure 7](#fig7){ref-type="fig"}B). We therefore generated variants with a nuclear localization signal (NLS) and transfected cells with nuclear-localized variants. This showed that the GFP-SUBs exclusively inhibited signaling in the cytoplasm because neither NLS-GFP-K63-SUB nor NLS-GFP-M1-SUB inhibited IL-8 production ([Figures 7](#fig7){ref-type="fig"}F and [S7](#mmc1){ref-type="supplementary-material"}A).

Consistent with an important function of Lys63-Ub for NOD2 signaling, depletion of Ubc13 inhibited IL-8 production to a similar extent as the depletion of HOIP ([Figure 7](#fig7){ref-type="fig"}G). Similar effects were obtained in cells where either CYLD or OTULIN was stably silenced, albeit the inhibitory effect of Ubc13 or HOIP depletion on IL-8 production was slightly less effective and depletion of both proteins was needed to completely prevent IL-8 production ([Figure 7](#fig7){ref-type="fig"}G). Altogether, our data reveal that the NOD2 pathway is exquisitely dependent on Lys63-Ub and Met1-Ub and suggest that the regulation of these linkages is coordinated by LUBAC through its associated DUBs CYLD and OTULIN.

Discussion {#sec3}
==========

In this study, we revealed that CYLD restricts deposition of Lys63-Ub and Met1-Ub on the LUBAC substrate RIPK2 to limit NOD2-dependent inflammatory signaling. We showed that CYLD, like OTULIN, interacts with LUBAC, suggesting that the Ub-regulating capacity of LUBAC complexes extends beyond Met1-Ub to also include Lys63-Ub.

There are several examples of Ub ligase-DUB pairs where a DUB either regulates substrate ubiquitination or auto-ubiquitination of the Ub ligase, notably the Mdm2-USP7 complex that regulates p53 stability and the DUB A20, which also harbors Ub ligase activity ([@bib41], [@bib49]). However, we are not aware of other examples than LUBAC-OTULIN-CYLD, where an Ub ligase associates with two separate DUB activities. It is possible that LUBAC exists as different complexes containing either CYLD or OTULIN because they both require residues within the PIM-binding pocket (e.g., N102) for interaction with HOIP. However, the LUBAC complex elutes as an ∼600-kDa complex and may thus contain two or more HOIP molecules, allowing for binding of both DUBs within the same complex ([@bib26]). Supporting the latter scenario, HOIP oligomerizes via the N-terminal part of the protein ([@bib12]), and CYLD has been shown to co-immunoprecipitate OTULIN in a LUBAC-dependent manner and vice versa ([@bib40]). Moreover, we found that the removal of Met1-Ub conjugated to HOIP was independent of CYLD but was entirely dependent on OTULIN's catalytic activity and its binding to LUBAC ([@bib12]), arguing for the existence of a ternary LUBAC-CYLD-OTULIN complex.

The molecular basis preventing CYLD from processing Met1-Ub on HOIP is not clear, but it could be via inaccessibility of CYLD, but not OTULIN, to the chains. OTULIN has high affinity for Met1 chains, several fold higher than reported for NEMO, the prototypical Met1-Ub-binding protein ([@bib24], [@bib34]). Possibly, HOIL-1 or another factor with Met1-Ub-binding capacity ([@bib17]) would prevent CYLD from gaining access to and cleaving the Met1-Ub on HOIP, whereas OTULIN would have access via its higher affinity toward Met1-Ub. However, further investigations are needed to uncover the basis of this differential role of CYLD and OTULIN in regulation of HOIP ubiquitination. It will also be of interest to investigate the possibility that HOIP ubiquitination could be an auto-regulatory mechanism controlled by OTULIN, for example, by inhibiting intrinsic LUBAC activity or affecting its recruitment to receptor complexes.

CYLD Regulation of LUBAC Substrates {#sec3.1}
-----------------------------------

An important insight from our study was that CYLD regulates the extension of Lys63 and Met1 linkages on RIPK2. Although depletion of CYLD resulted in extended Ub modifications on RIPK2 (and RIPK1 after TNF treatment), the full extent of regulation of RIPK2 ubiquitination by CYLD (and OTULIN) was uncovered only when we functionally inhibited IAP proteins. CYLD also regulated the ubiquitination of RIPK1, but inhibition of IAP proteins had a less dramatic effect. This suggests that deposition of Ub modifications at the NOD2 complex, the TNFR1 complex, and possibly other immune complexes is continuously coordinated through the opposing activities of Ub ligases and DUBs. This could enable dynamic alterations to the linkage composition of Ub chains within these signaling complexes. Such a mechanism is described for A20, which removes Lys63 linkages and assembles Lys48-Ub to terminate signaling ([@bib49]). In response to IL-1R stimulation, Met1 linkages are formed almost exclusively on existing Lys63-Ub conjugated to IRAK1, a component of the MyD88 signalosome ([@bib13]). Analogously, the Ub-linkage composition of Ub-RIPK2 following NOD2 stimulation showed that Lys63-Ub is the first linkage type conjugated to RIPK2 whereas Met1 linkages are formed only on RIPK2 molecules that are already polyubiquitinated ([@bib15]). An intriguing possibility is that CYLD functions to trim Lys63-linked Ub chains to facilitate their Met1 ubiquitination by LUBAC.

Of note, during revision of this manuscript, a study by [@bib11] reported that OTULIN was not stably associated with receptor-signaling complexes and suggested that OTULIN does not regulate ubiquitination of RIPK2. However, the data presented here and in our previous study ([@bib15]) indicate that OTULIN has access to the endogenous NOD2 complex (irrespective of whether it associates stably or not), where it restricts RIPK2 ubiquitination alongside CYLD. The underlying reason for the discrepancy is not clear at this time but could be due to a difference in experimental approaches.

Functional Role of CYLD and Lys63-Ub {#sec3.2}
------------------------------------

The functional requirement of Lys63-Ub for immune receptor signaling is controversial and appears to be specific to individual receptor systems ([@bib32], [@bib46], [@bib50]). It was therefore important to establish whether or not K63-Ub contributes to NOD2 signaling. Using linkage-selective Ub binders to interfere with Lys63-Ub function together with silencing of the E2 Ubc13, we established that Lys63 linkages are essential for productive NOD2 signaling. Interestingly, the NOD2 pathway is equally dependent on LUBAC function and Met1-Ub ([@bib8], [@bib47]), illustrating the non-redundant signaling properties of these linkages. In contrast, Lys63-Ub is reported to be largely dispensable in the TNFR1 pathway ([@bib46], [@bib50]), and although Met1-Ub contributes to pro-inflammatory signaling, it also has a prominent role in regulating the formation of cell death complexes ([@bib16], [@bib21], [@bib24]). The molecular basis underlying the receptor-specific functions of Lys63- and Met1-Ub is not understood, but it might reflect how ubiquitination is coordinated at receptor complexes. For example, the generation of Lys63/Met1 hybrid chains in the IL-1R pathway probably explains the exquisite dependency on the Lys63 linkage within the system ([@bib13]).

Even though CYLD is well known to regulate inflammation and innate immune responses, its role in regulating the NOD2 pathway had not been defined. In line with the requirement of Lys63- and Met1-Ub in NOD2, but not TNFR1, signaling, we found that endogenous CYLD was critical for limiting productive NOD2 signaling but that it did not appreciably affect TNF signaling as judged by IL-8 production. Interestingly, CYLD is reported to negatively regulate the innate immune response to infection by *Listeria monocytogenes*, an intracellular bacterial pathogen recognized by NOD1 and NOD2 ([@bib25], [@bib31]). This suggests that the regulation of RIPK2 ubiquitination by CYLD (and LUBAC and OTULIN) could influence the response to infection by intracellular bacteria.

In conclusion, our study exemplifies how ubiquitination following innate immune receptor activation is carefully controlled by LUBAC and its associated DUB activities CYLD and OTULIN for accurate regulation of downstream signaling and pro-inflammatory responses.

Experimental Procedures {#sec4}
=======================

Purification of Endogenous Ub Conjugates {#sec4.1}
----------------------------------------

Ub conjugates were purified from cell lysates using affinity reagents TUBE, M1-SUB, and K63-SUB ([@bib15], [@bib43]) or UBA^Ubq^. Briefly, cells were lysed in buffer containing 20 mM Na~2~HPO~4~, 20 mM NaH~2~PO~4~, 1% (v/v) NP-40, and 2 mM EDTA and supplemented with 5 mM N-ethylmaleimide, cOmplete protease inhibitors, and PhosSTOP (Roche). The affinity reagents TUBE (50 μg/ml), M1-SUB (100 μg/ml), K63-SUB (15 μg/ml), or UBA^Ubq^ (150 μg/ml) were either added directly to the cell lysates or pre-bound to Glutathione Sepharose 4B beads (GE Healthcare) for at least 1 hr. For K63-SUB pull-down, the Thermo Scientific Pierce Streptavidin Magnetic Beads were washed in lysis buffer and incubated with the biotinylated K63-SUB in the lysis buffer for at least 1 hr agitating at 4°C, followed by three washes. For all pull-downs, lysates were cleared by centrifugation, mixed with beads, and incubated agitating at 4°C for a minimum of 2 hr. The beads were washed four times in 500 μl of ice-cold PBS 0.1% (v/v) Tween-20 or TUBE lysis buffer. The bound material was eluted with 15 mM glutathione in PBS or with 1× sample loading buffer.

Immunofluorescence Staining and Confocal Microscopy {#sec4.2}
---------------------------------------------------

Low-density U2OS/NOD2 cell cultures grown on coverslips were transfected using Fugene6 (Promega) according to manufacturer's protocol. After 24 hr, the cells were stimulated with 1 μg/ml L18-MDP for 1 hr. The cells were fixed in 4% formaldehyde and permeabilized by 0.1% (v/v) Triton X-100 in PBS. Blocking was performed in 5% (w/v) BSA and 0.01% (v/v) Triton X-100 in PBS, and cells were stained with primary antibodies and fluorescently labeled secondary antibodies in the blocking solution for 1 hr at room temperature. The nuclei were stained with 1 μg/ml DAPI for 10 min. Coverslips were mounted on slides using ProLong Gold Antifade Reagent (Life Technologies). Images were acquired on a Carl Zeiss LSM710 confocal microscope equipped with 20× dry and 63× oil lenses. To quantify RelA translocation, images were semi-automatically processed in FiJi software using a macro. Briefly, nuclear staining (DAPI channel) was used to create a mask, which was used to measure fluorescence intensities in green (transfected cells) and red (RelA) channels.

Intracellular Flow Cytometry of IL-8 {#sec4.3}
------------------------------------

U2OS/NOD2 cells, transfected using Fugene6, were stimulated 24--48 hr after transfection with 200--300 ng/ml L18-MDP for 4--6 hr in the presence of 5 μg/ml Brefeldin A and 2 μM Monensin (BioLegend) protein transport inhibitors. After stimulation, cells were washed with PBS, dissociated by Trypsin/EDTA solution (GIBCO Life Technologies), and collected by centrifugation. Cells were fixed with IC Fixation Buffer (eBioscence) O/N at 4°C; washed with PBS; permeabilized using Perm/Wash Buffer containing 2% (v/v) FCS, 0.1% (w/v) saponin, and 0.1% (w/v) NaN~3~ in PBS; and incubated in the Perm/Wash Buffer with anti-IL-8/allophycocyanin (APC) for 1 hr at room temperature. The cells were analyzed by FACS Canto Flow Cytometer (BD Bioscience) and data processed using FlowJo software (TreeStar). APC and GFP levels were acquired using 633 nm and 488 nm laser, respectively.

DUB Assays {#sec4.4}
----------

Ub conjugates from L18-MDP-treated cells were isolated by M1-SUB (100 μg/ml) or GST-UBA^Ubq^ (150 μg/ml) pre-bound to GST beads as described under purification of endogenous Ub conjugates. After wash, beads were resuspended in DUB buffer (50 mM HEPES \[pH 7.5\], 100 mM NaCl, 2 mM DTT, 1 mM MnCl~2~, and 0.01% Brij-35). For siMM/shMM or siCYLD/shCYLD U2OS/NOD2 experiments, Ub conjugates incubated without or with DUBs (USP21 \[0.5 μM\], OTULIN \[0.4--1 μM\], OTULIN C/A \[1 μM\], vOTU \[0.4 μM\], OTUB1 \[15 μM\], OTUD1 \[0.2 μM\], and AMSH^∗^ \[3 μM\]). Samples were incubated for 15 min ([Figure 6](#fig6){ref-type="fig"}B) or 1 hr ([Figure 6](#fig6){ref-type="fig"}A). For the time course experiment, DUBs OTUD1 (0.2 μM) and OTULIN (0.4 μM) incubated with the Ub conjugates for 15, 60, or 240 min and USP21 (0.5 μM) and the no DUB control incubated for 60 min. For spiked in GST-Met1-Ub4 experiments, 4 μg was added to the Ub conjugates and incubated with DUBs (OTULIN \[0.4 μM\] and OTUD1 \[0.2 μM\]) or no DUB for 4 hr. For the THP1 cells, Ub conjugates incubated for 1 hr with or without DUBs OTULIN (1 μM), OTUD1 (1 μM), and Usp21 (0.5 μM). All samples incubated at 30°C with shaking, and loading sample buffer was added to stop the reaction.

Cytometric Bead Array {#sec4.5}
---------------------

Secreted cytokines (Il-1β, IL-6, and TNF) were measured from culture supernatants from BMDC after 24 hr with or without MDP with the Cytometric Bead Array (CBA) (BD Biosciences) according to manufacturer's protocol.

Generation of Stable CRISPR/Cas9 HCT-116 Cells {#sec4.6}
----------------------------------------------

To generate stable HCT-116 knockout cell lines, the cells were transfected using Fugene HD with the RNF31 CRISPR/Cas9 KO Plasmid (sc-412436; Santa Cruz Biotechnology) containing gRNA, Cas9, and EGFP marker. After 36 hr, top 10% of GFP-positive cells were sorted by flow cytometry and cloned by limiting dilution to obtain single-cell clones. Individual clones were validated by western blotting with HOIP-specific antibodies.

Statistical Analysis {#sec4.7}
--------------------

Statistical analysis was performed in Using Prism 6 (GraphPad Software). The two-tailed Student's tests were used to determine statistical significance in [Figures 1](#fig1){ref-type="fig"}D, [3](#fig3){ref-type="fig"}D, and 3E; at all other instances, two-way ANOVA was used to determine statistical significance.
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![CYLD Antagonizes LUBAC Function but Does Not Affect HOIP Ubiquitination\
(A) Immunoprecipitation of endogenous SHARPIN from control (MM) and HOIP-depleted U2OS/NOD2 cells. Lysates and immunoprecipitated material were examined by immunoblotting.\
(B) Immunoprecipitation of exogenous FLAG-tagged CYLD. Lysates and immunoprecipitated material were examined for copurification of HOIP.\
(C) Immunoprecipitation of exogenous V5-tagged HOIP^WT^, HOIP^PUB+NZF^, and HOIP^N102D^ expressed in HEK293FT cells. Immunoprecipitated material was examined for copurification of OTULIN and CYLD.\
(D) NF-κB activity in HEK293FT cell lysates transfected with dual luciferase reporters, co-expressed with vector LUBAC (HOIL-1/HOIP), OTULIN, or CYLD variants as indicated. Luciferase activity is shown relative to the activity in LUBAC-transfected cells.\
(E) Purification of endogenous Ub conjugates using UBA^Ubq^, M1-SUB, or K63-SUB in U2OS/NOD2 cell lysates stably depleted for CYLD or OTULIN and treated with L18-MDP (200 ng/ml; 1 hr) or TNF (10 ng/ml; 10 min). Purified material and lysates were examined by immunoblotting.\
(F and G) Purification of endogenous Ub conjugates in THP1 cells (F) or HCT-116 cells (G) stably depleted for CYLD or OTULIN and treated with L18-MDP (200 ng/ml; 1 hr) or TNF (10 ng/ml; 10 min). Purified material and lysates were examined by immunoblotting.\
(H) Purification of endogenous Ub conjugates in HEK293FT cell lysates transfected with OTULIN or CYLD variants co-expressed with LUBAC as indicated. Purified material and lysates were examined by immunoblotting.\
Data in (D) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![CYLD Restricts NOD2 Signaling and Cytokine Production\
(A) Relative levels of *TNF* and *CXCL8* transcripts from U2OS/NOD2 control (siMM) and CYLD-depleted (siCYLD) cells treated with L18-MDP (200 ng/ml; 3 hr) normalized to untreated siMM.\
(B) Intracellular flow cytometry analysis of IL-8 in shRNA control (shMM) U2OS/NOD2 cells or cells stably depleted for OTULIN (shOTLN) or CYLD (shCYLD) in response to L18-MDP (200 ng/ml; 4 hr) or TNF (10 ng/ml; 4 hr).\
(C) WT and *Cyld*^*−/−*^ BMDCs were stimulated with MDP (10 μg/ml; 24 hr), and secreted cytokines were measured in culture supernatants.\
(D) Intracellular flow cytometry analysis of IL-8 in U2OS/NOD2 cells depleted for OTULIN (siOTLN) and CYLD (siCYLD) or control (siMM) using siRNA oligos in response to L18-MDP (200 ng/ml; 4 hr).\
(E) Immunoblot of HOIP levels in control HCT-116 cells and in CRISPR/Cas9 HOIP KO cells.\
(F) Relative levels of *CXCL8* transcripts from HCT-116 WT and HOIP KO cells treated with L18-MDP (200 ng/ml) and TNF (10 ng/ml) for the indicated times and normalized to untreated control cells. Data are shown on a two-segmented y axis.\
Data in (A), (B), (D), and (F) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01; *n.s*. not significant. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![CYLD Catalytic Activity Inhibits the NOD2 Pathway Upstream of Nuclear Translocation of NF-κB\
(A) Immunofluorescence analysis of nuclear translocation of the NF-κB subunit RelA/p65 (red) in response to L18-MDP (1 μg/ml; 1 hr) in U2OS/NOD2 cells transfected with FLAG-CYLD variants and stained with anti-FLAG (green; scale bar, 10 μm).\
(B) Quantification of cells with nuclear RelA treated as in (A).\
(C) Intracellular flow cytometry analysis of IL-8 in U2OS/NOD2 cells transfected with FLAG-CYLD variants in response to L18-MDP (200 ng/ml; 4 hr). Cells were cotransfected with a GFP vector (ratio 1:10) as a marker of transfection.\
(D) NF-κB activity in HEK293FT cell lysates transfected with dual luciferase reporters, XIAP, CYLD, and OTULIN as indicated. Values are expressed relative to XIAP transfection.\
(E) NF-κB activity in HEK293T cell lysates transfected with luciferase reporters, vector, or XIAP and depleted for Ubc13 using two different siRNAs. Values are expressed relative to XIAP transfection.\
Data in (B)--(E) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01; ^∗^p \< 0.05. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![CYLD Limits Extension of Ub Chains on RIPK Proteins\
(A) Purification of Ub conjugates from U2OS/NOD2 cells at indicated time points after treatment with L18-MDP (200 ng/ml). Purified material was examined for ubiquitinated RIPK2 by immunoblotting.\
(B) Purification of Ub conjugates from control or OTULIN- or CYLD-depleted U2OS/NOD2 cells treated with L18-MDP (200 ng/ml; 1 hr). Purified material and lysate were examined by immunoblotting.\
(C and D) Relative mRNA (C) and protein (D) levels of *CYLD*, *OTULIN*, and *TNFAIP3* (*A20*) upon L18-MDP stimulation (200 ng/ml) of U2OS/NOD2 cells at the time points indicated. Asterisk denotes unspecific band detected by the antibody.\
(E) Purification of Ub conjugates from U2OS/NOD2 cells treated with TNF (10 ng/ml; 10 min). Purified material and lysate were examined for RIPK1 by immunoblotting.\
(F) Purification of TNFR-SC from U2OS/NOD2 cells stimulated with FLAG-TNF using anti-FLAG agarose and analyzed by immunoblotting.\
(G) Immunoprecipitation of HA-NOD2 from U2OS/NOD2 cells. HA-NOD2 expression was induced with DOX (2 μg/ml) for 24 hr. Immunoprecipitates were examined for co-purification of CYLD and other members of the NOD2 receptor complex.\
Data in (C) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Inhibition of IAPs Reveals Extensive Regulation of RIPK2 Ubiquitination by CYLD and OTULIN\
(A and B) Purification of endogenous Ub conjugates from U2OS/NOD2 cells depleted for CYLD or OTULIN by siRNA. Cells were pre-treated with DMSO (control) or with 1 μM compound A (CpA) for 30 min before stimulation with (A) L18-MDP (200 ng/ml; 1 hr) or (B) TNF (10 ng/ml; 10 min).\
(C and D) Intracellular flow cytometry analysis of IL-8 in control (MM) U2OS/NOD2 cells or cells depleted for CYLD or OTULIN by siRNA pre-treated with 1 μM CpA for 30 min before stimulation with (C) L18-MDP (200 ng/ml; 4 hr) or (D) combination of phorbol myristate acetate (PMA) (50 ng/ml) and ionomycin (500 μM) for 4 hr. Data in (C) and (D) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![CYLD Trims Lys63- and Met1-Ub on RIPK2\
(A) UbiCRest analysis of ubiquitinated RIPK2 isolated with M1-SUB from L18-MDP-treated (200 ng/ml; 1 hr) control (siMM) or CYLD-depleted (siCYLD) U2OS/NOD2 cells. Purified Ub conjugates were incubated with the indicated DUBs for 1 hr, and samples were examined by immunoblotting.\
(B) As in (A) except ubiquitinated RIPK2 was isolated with GST-UBA^Ubq^ followed by incubation with the indicated DUBs for 15 min and cells were stably depleted for CYLD (shCYLD) or control (shMM). Black dashed line separates two scans of the same membrane but with slightly different exposure.\
(C) As in (B) except that Ub conjugates were purified from THP-1 cells and incubated for 1 hr.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Lys63-Ub and Met1-Ub Are Individually Indispensable for NOD2 Signaling\
(A) Schematic representation of the GFP-tagged Ub-binding constructs used for transient expression in cells (GFP-M1-SUB: UBAN domain from NEMO; GFP-K63-SUB: three UIMs from RAP80 in tandem).\
(B) Immunofluorescence analysis of nuclear translocation of RelA (red) in response to L18-MDP stimulation (1 μg/ml; 1 hr) or no treatment (NT) in U2OS/NOD2 cells transfected with GFP, GFP-K63-SUB, or GFP-M1-SUB (green) for 24 hr. The scale bar represents 10 μm.\
(C) Quantification of (B).\
(D) Intracellular flow cytometry analysis of IL-8 in U2OS/NOD2 cells transfected as indicated for 48 hr before L18-MDP stimulation (200 ng/ml; 4 hr).\
(E) Gating of cells in (D) based on GFP levels (relative fluorescence units \[RFUs\]). RFU values on x axis indicate the maximal RFU in each gate with the previous value defining the lower limit, except of the "zero" RFU population, which includes cells with values up to 100 RFUs.\
(F) As in (D) except that GFP, GFP-K63-SUB, or GFP-M1-SUB contains a nuclear localization signal (NLS).\
(G) Intracellular flow cytometry analysis of IL-8 in control (MM) U2OS/NOD2 cells or cells stably depleted for CYLD or OTULIN; depleted for HOIP, Ubc13, or both by siRNA as indicated; and treated with L18-MDP (200 ng/ml; 4 hr) or not treated (NT).\
Data in (C)--(G) represent the mean ± SEM of at least three independent experiments, each performed in duplicate. ^∗∗^p \< 0.01. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
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